Post hoc data from 2 late-stage studies about siponimod, sold as Mayzent by Novartis, illustrated improved cognitive processing speed and delayed time to disability in multiple sclerosis.
When used early in multiple sclerosis, siponimod (Mayzent) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS), according to Novartis. The benefits were sustained for up to 5 years.
The data were released during MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting taking place September 11–13, 2020.
Siponimod is an oral selective sphingosine 1-phosphate (S1P) receptor modulator that may directly prevent degeneration of nerve fibers. It was approved in 2019 and was the first SPMS treatment to be approved in 15 years; it is also indicated for relapsing multiple sclerosis (RMS).
One analysis assessed the long-term efficacy and safety of siponimod in patients with active SPMS (aSPMS) from the pivotal EXPAND study.1 Patients with aSPMS are had a relapse 2 years prior to screening and/or had a lesion at baseline. End points were 6-month confirmed disability progression (6mCDP) and 6-month confirmed cognitive worsening (6mCCW).
Of the 1651 patients randomized in the core group, 1224 entered the extension. Of the 779 patients with aSPMS from the core group, 516 had been taking the drug continuously, and 263 had switched from placebo to siponimod in the extension; 582 entered this part of the extension.
The risk of 6mCDP was reduced by 29% (HR, 0.71; 95% CI, 0.57-0.90; P = .0044) for the continuous versus switch group, translating to about a 70% delay in time to 6mCDP across the 25th to 40th percentile.
Median time to 6mCDP was 48 months for the switch group, but was not reached for the continuous group.
The risk of 6mCCW for the continuous versus the switch group was reduced by 33% (HR, 0.67; 95% CI, 0.53-0.86; P = .0018), corresponding to about a 70% delay in time to 6mCCW across the 25th to 30th percentile.
Median time to 6mCCW (55.5 months) was reached only for the switch group.
In addition, a significant reduction in annualized relapse rate (ARR) for the continuous versus switch groups was observed in patients with (0.08 vs 0.12; P = .0023) or without active disease (0.03 vs 0.08; P < .0001).
Another poster examined the effect of siponomid on cognitive processing speed in patients with SPMS with both active and non-active disease by measuring improvement in the Symbol Digit Modalities Test (SDMT).2
Researchers were looking for a change in SDMT score by 4 points or more from baseline to month 24, as well as the proportion of patients with worsened, stable and improved SDMT scores at month 24.
Results showed that the drug “showed significant benefits in cognitive processing speed as measured by SMDT change from baseline in patients with both active and non-active SPMS,” according to a recorded presentation.
Change in SDMT (95% CI) versus placebo from baseline to month 24 in patients with aSPMS and non-active SPMS was 2.34 (0.66-4.02) and 2.44 (0.67-4.22; P <.01 for both, respectively).
In the aSPMS group, a lower proportion of patients worsened (27.3% vs 38.2%, P = .002) and a higher proportion of patients improved (34.1% vs 22.9%, P = .001) on SDMT versus placebo.
A similar but non-significant trend was seen in patients with non-active SPMS.
“The data presented today reinforces that through its beneficial effects on cognitive performance and delaying disability progression, and as an appropriate option for patients to safely switch to/from other treatments, Mayzent offers hope for people looking to achieve this important goal,” Norman Putzki, MD, Global Head of Development, Neuroscience, said in a statement.
References
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More